SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

NARCAN

EBS·Emergent BioSolutions Inc.
BEARISH
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (OTC since March 2023).
Why 4/10
NARCAN is already approved and commercialized with no pending PDUFA date or pivotal readout scheduled in the next ~12 months. The defining binary (OTC approval in March 2023) has passed. ImpactScore is 4 because while NARCAN is a major product for Emergent, the commercial trajectory (declining sales from competition) is not a hard binary catalyst.
Actionable Insight BEARISH

Watch for continued erosion of NARCAN market share as three OTC competitors (RiVive, Rextovy, and Amneal's generic) intensify pricing pressure. Emergent's Q3 2026 earnings (Nov 2) showed naloxone revenue down 42% YoY, and the company cut full-year guidance. The next major catalyst is the Q4 2026 earnings report in early 2027, which will show whether the multipack strategy and Canadian expansion can offset U.S. market share losses.

Price Chart

Loading chart...

Executive Summary

NARCAN (naloxone HCl nasal spray 4 mg) is Emergent BioSolutions' over-the-counter opioid overdose reversal product, first approved by the FDA in 2015 (prescription) and switched to OTC in March 2023 as the first nonprescription naloxone product. While NARCAN was a first-mover in the OTC space, it now faces at least three OTC competitors (RiVive, Rextovy/Amphastar, and Amneal's generic), driving aggressive pricing pressure. Naloxone revenue fell 42% YoY in Q3 2026, and Emergent recorded a $191.3M impairment on the NARCAN asset group in Q2 2026. The stock fell ~25% in after-hours trading on Nov 2, 2026 after reporting Q3 results and cutting full-year guidance. NARCAN is already approved with no upcoming binary regulatory catalysts.

How It Works

NARCAN (naloxone) is an opioid antagonist that rapidly reverses the effects of an opioid overdose by binding to opioid receptors in the brain and blocking or displacing opioids like heroin, fentanyl, or prescription painkillers. It is administered as a nasal spray and can restore normal breathing within minutes in a person whose breathing has slowed or stopped due to an opioid overdose.

Trial Status

NARCAN is an FDA-approved, commercially marketed product. Supplemental NDAs for new carrying case packaging (January 2026) and multipack configurations (February 2026) were approved. No clinical trials are ongoing for the approved formulation.

The Two-Sided Case

▲ Bull Case5
NARCAN was the first FDA-approved OTC naloxone product (March 2023) and remains the most recognized brand in the opioid overdose reversal market.
FDA approved new multipack configurations (6-count and 24-count) in February 2026, potentially improving cost-effectiveness and distribution efficiency.
Canadian sales of branded NARCAN partially offset U.S. declines in Q3 2026, and Emergent won a Canadian standing offer running through September 2029.
Analyst consensus shows 5 Buy/Strong Buy ratings vs 1 Hold and 1 Sell, with a mean price target of $11 (61.5% implied upside from the $6.81 close).
Several large institutional investors added or doubled positions in Q2 2026, including Millennium Management, Goldman Sachs, and Prudential Financial.
▼ Bear Case5
NARCAN faces at least three OTC competitors: RiVive (Harm Reduction Therapeutics), Rextovy (Amphastar, approved June 2026), and Amneal's generic OTC naloxone, all driving aggressive pricing pressure.
Naloxone product revenue fell 42% YoY in Q3 2026 ($31.4M decline), driven by unfavorable price-volume mix in U.S. public interest channels.
Emergent recorded a $191.3M non-cash impairment on the NARCAN asset group in Q2 2026, reflecting management's reduced cash flow expectations.
Full-year 2026 revenue guidance was cut to $600-$645M, and Q3 GAAP gross margin collapsed to 14% from 54% a year earlier.
The stock fell ~25% in after-hours trading on Nov 2, 2026 after Q3 earnings, trading at $5.12.

Upcoming Catalysts

  • Q4 2026 / full-year 2026 earnings report (early 2027) - will show whether NARCAN revenue decline is stabilizing or accelerating
  • Further competitive dynamics as additional OTC naloxone entrants potentially launch
  • Any further label expansion or packaging sNDA approvals

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Emergent BioSolutions Inc. 8-K EBS ·Originating report

Sources · 8

Hover a chip for the title
1 investors.emergentbiosolutions.com2 fda.gov3 techtimes.com4 tradingkey.com5 ainvest.com6 investors.emergentbiosolutions.com7 marketbeat.com8 nwvcil.org